| Literature DB >> 24269911 |
Daniël Bossen1, Cindy Veenhof, Karin Ec Van Beek, Peter Mm Spreeuwenberg, Joost Dekker, Dinny H De Bakker.
Abstract
BACKGROUND: Patients with knee and/or hip osteoarthritis (OA) are less physically active than the general population, while the benefits of physical activity (PA) have been well documented. Based on the behavioral graded activity treatment, we developed a Web-based intervention to improve PA levels in patients with knee and/or hip OA, entitled "Join2move". The Join2move intervention is a self-paced 9-week PA program in which the patient's favorite recreational activity is gradually increased in a time-contingent way.Entities:
Keywords: Web-based intervention; osteoarthritis; physical activity; randomized controlled trial
Mesh:
Year: 2013 PMID: 24269911 PMCID: PMC3841352 DOI: 10.2196/jmir.2662
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Join2move homepage.
Figure 2Flow of participants throughout the trial.
Baseline demographic and clinical characteristics.
| Characteristic |
| Intervention, n=100 | Control, n=99 |
|
|
| ||||
|
| Male | 40 (40.0) | 30 (30.3) | .15 |
|
| Female | 60 (60.0) | 69 (69.7) |
|
| Age (years), mean (SD) |
| 61 (5.9) | 63 (5.4) | .05 |
| BMI (kg/m2), mean (SD) |
| 27.6 (4.6) | 27.5 (4.5) | .79 |
|
| ||||
|
| Knee | 67 (67.0) | 60 (60.6) | .37 |
|
| Hip | 21 (21.0) | 20 (20.2) |
|
|
| Both | 12 (12.0) | 19 (19.2) |
|
|
| ||||
|
| ≤1 year | 12 (12.0) | 6 (6.1) | .33 |
|
| >1-3 years | 28 (28.0) | 27 (27.3) |
|
|
| >3-7 years | 27 (27.0) | 27 (27.3) |
|
|
| ≥7 years | 33 (33.0) | 39 (39.4) |
|
|
| ||||
|
| Low education | 13 (13.0) | 15 (15.2) | .36 |
|
| Middle education | 36 (36.0) | 43 (43.4) |
|
|
| High education | 51 (51.0) | 40 (40.4) |
|
|
| ||||
|
| None | 65 (65.0) | 60 (60.6) | .43 |
|
| One | 19 (19.0) | 16 (16.2) |
|
|
| Two or more | 16 (16.0) | 23 (23.2) |
|
Figure 3Module completion rate.
Primary outcome measures: improvements and differences between groupsa.
| Outcome measures | n | Intervention, mean (95% CI) | n | Control, mean (95% CI) | Difference, I-Cb(95% CI) | ES |
| |
|
| ||||||||
|
| Baseline | 100 | 163 (130-196) | 97 | 160 (123-197) | — | — | — |
|
| 3 months | 85 | 162 (136-187) | 79 | 163 (137-190) | −1.6 (−16.6 to 13.5) | −0.01 | .84 |
|
| 12 months | 74 | 174 (150-198) | 71 | 153 (125-181) | 21.2 (3.6-38.9) | 0.18 | .02 |
|
| ||||||||
|
| Baseline | 39 | 369 (299-439) | 40 | 395 (322-468) | — | — | — |
|
| 3 months | 27 | 361 (312-411) | 30 | 358 (310-407) | 3 (−26 to 32) | 0.02 | .83 |
|
| 12 months | 24 | 361 (317-406) | 28 | 338 (291-384) | 24 (0.5-46.8) | 0.19 | .045 |
|
| ||||||||
|
| Baseline | 99 | 58.8 (51.5-66.0) | 98 | 55.2 (47.9-62.5) | — | — | — |
|
| 3 months | 84 | 67.8 (59.2-76.4) | 80 | 61.3 (52.7-69.9) | 6.5 (1.8-11.2) | 0.20 | .006 |
|
| 12 months | 75 | 67.9 (59.1-76.7) | 72 | 62.9 (54.1-71.7) | 5.0 (−1.0 to 11.0) | 0.17 | .1 |
|
| ||||||||
|
| 3 months, n (%) improved | 85 | 44 (44) | 83 | 7 (7.1) | 10.7c (4.3-26.4) | — | <.001 |
|
| 12 months, n (%) improved | 76 | 34 (34) | 74 | 27 (27.3) | 1.2c (0.6-2.4) | — | .5 |
aFor PA, physical functioning, and self-perceived effect, a higher score indicates an improvement. Results are based on GEE analyses and adjusted for corresponding baseline variables, age, OA location, and gender.
bI-C: difference between intervention and control group.
codds ratio
Secondary outcome measures: improvements and differences between groupsa.
| Outcome measures | n | Intervention, mean (95% CI) | n | Control, mean (95% CI) | Difference, I-Cb(95% CI) | ES |
| |
|
| ||||||||
|
| Baseline | 39 | 571 (498-645) | 40 | 555 (479-630) | — | — | — |
|
| 3 months | 27 | 508 (454-563) | 30 | 540 (477-603) | −32 (−67.7 to 3.7) | −0.20 | .08 |
|
| 12 months | 24 | 514 (448-580) | 28 | 531 (467-595) | −17 (−54.7 to 20.7) | −0.10 | .38 |
|
| ||||||||
|
| Baseline | 100 | 5.4 (4.2-6.5) | 98 | 4.9 (3.7-6.1) |
|
|
|
|
| 3 months | 85 | 3.5 (2.5-4.6) | 81 | 4.5 (3.4-5.7) | −1 (−1.6 to −0.38) | −0.20 | .002 |
|
| 12 months | 76 | 3.5 (2.4-4.5) | 71 | 3.8 (2.7-4.9) | −0.36 (−1.1 to 0.38) | −0.07 | .33 |
|
| ||||||||
|
| Baseline | 100 | 5.6 (4.3-6.9) | 99 | 5.5 (4.3-6.8) | — | — | — |
|
| 3 months | 85 | 3.2 (2-4.4) | 81 | 4.1 (2.9-5.3) | −0.84 (−1.6 to -0.06) | −0.16 | .04 |
|
| 12 months | 76 | 3 (1.9-4.2) | 71 | 4.1 (3-5.2) | −1.15 (−1.9 to −0.28) | −0.22 | .008 |
|
| ||||||||
|
| Baseline | 100 | 68.2 (60.2-76.2) | 99 | 70.9 (62.7-79.2) | — | — | — |
|
| 3 months | 85 | 67.4 (59.1-75.8) | 80 | 64.3 (55.3-73.2) | 3.1 (−1.3 to 7.6) | 0.08 | .16 |
|
| 12 months | 76 | 65.7 (57.4-74.0) | 71 | 62.8 (53.4-72.1) | 3 (−2.1 to 8.1) | 0.08 | .25 |
|
| ||||||||
|
| Baseline | 100 | 38 (30.6-45.5) | 98 | 40.9 (33.6-48.2) | — | — | — |
|
| 3 months | 85 | 49.4 (41.7-57.0) | 80 | 47.3 (39.4-55.1) | 2.1 (−1.7 to 5.9) | 0.06 | .28 |
|
| 12 months | 75 | 48.7 (40.8-56.6) | 71 | 47.5 (39.3-55.6) | 1.2 (−4.4 to 6.8) | 0.03 | .68 |
|
| ||||||||
|
| Baseline | 88 | 27.6 (14.7-40.4) | 78 | 27.6 (13.4-41.9) | — | — | — |
|
| 3 months | 58 | 42.6 (29.6-55.6) | 55 | 42.6 (29-56.2) | 0 (−8.0 to 8.1) | 0 | 1 |
|
| 12 months | 53 | 42.4 (28.1-56.8) | 47 | 39.6 (25.6-53.5) | 2.9 (−6.3 to 12.1) | 0.08 | .54 |
|
| ||||||||
|
| Baseline | 100 | 4.1 (3.6-4.6) | 97 | 3.8 (3.6-4.2) | — | — | — |
|
| 3 months | 85 | 4 (3.6-4.4) | 79 | 3.7 (3.3-4.1) | 0.31 (0.1-0.5) | 0.17 | .008 |
|
| 12 months | 75 | 4 (3.6-4.4) | 72 | 3.9 (3.5-4.3) | 0.12 (−01 to 0.4) | 0.06 | .35 |
|
| ||||||||
|
| Baseline | 100 | 3.6 (3.1-4.1) | 96 | 3.8 (3.4-4.3) | — | — | — |
|
| 3 months | 85 | 4 (3.7-4.4) | 79 | 3.8 (3.7-4.4) | 0.21 (0-0.4) | 0.12 | .07 |
|
| 12 months | 75 | 4.1 (3.7-4.4) | 72 | 3.8 (3.5-4.2) | 0.23 (0-0.5) | 0.20 | .05 |
|
| ||||||||
|
| Baseline | 100 | 2.2 (2.0-2.4) | 96 | 2.2 (2-2.4) | — | — | — |
|
| 3 months | 83 | 2 (1.9-2.2) | 77 | 2 (1.8-2.2) | −0.02 (−0.1 to 0.1) | −0.02 | .81 |
|
| 12 months | 73 | 2 (1.8-2.2) | 70 | 2 (1.8-2.2) | 0 (−0.1 to 0.1) | 0 | .98 |
|
| ||||||||
|
| Baseline | 100 | 1.8 (1.7-2.0) | 96 | 1.8 (1.6-1.9) | — | — | — |
|
| 3 months | 83 | 1.7 (1.6-1.8) | 77 | 1.7 (1.6-1.9) | −0.04 (−0.1 to 0.04) | 0 | .29 |
|
| 12 months | 73 | 1.7 (1.5-1.8) | 70 | 1.8 (1.7-1.9) | −0.12 (−0.2 to –0.03) | −0.18 | .008 |
|
| ||||||||
|
| Baseline | 100 | 27.1 (25.1-29.2) | 96 | 27.5 (25.2-29.8) | — | — | — |
|
| 3 months | 84 | 23.9 (21.9-25.8) | 79 | 23.4 (21.3-25.6) | 0.45 (−0.6 to 1.5) | 0.06 | .41 |
|
| 12 months | 74 | 23.6 (21.7-25.6) | 70 | 24 (21.7-26.2) | −0.3 (−1.5 to 0.9) | −0.05 | .61 |
|
| ||||||||
|
| Baseline | 99 | 17.4 (14.8-20.0) | 96 | 18.8 (15.8-21.8) | — | — | — |
|
| 3 months | 83 | 16.5 (15.0-18.0) | 79 | 16.1 (14.3-18.0) | 0.37 (−0.8 to 1.5) | 0.05 | .53 |
|
| 12 months | 73 | 15.2 (13.6-6.9) | 70 | 16 (14.1-17.9) | −0.74 (−2.0 to 0.6) | −0.1 | .26 |
|
| ||||||||
|
| Baseline | 100 | 4 (2.5-5.6) | 97 | 4.2 (2.6-5.9) | — | — | — |
|
| 3 months | 85 | 3.5 (2.5-4.5) | 79 | 4.2 (3.1-5.2) | −0.64 (−1.3 to 0) | −0.15 | .05 |
|
| 12 months | 75 | 3.1 (2.0-4.3) | 72 | 4.1 (2.9-5.2) | −0.9 (−1.6 to −0.2) | −0.21 | .007 |
|
| ||||||||
|
| Baseline | 100 | 4 (2.5-5.6) | 96 | 4.2 (2.6-5.9) | — | — | — |
|
| 3 months | 85 | 2.6 (1.5-3.7) | 78 | 3.2 (2.1-4.3) | −0.61 (−1.3 to 0.1) | −0.12 | .09 |
|
| 12 months | 75 | 2.4 (1.3-3.6) | 72 | 3 (1.9-4.2) | −0.6 (−1.3 to 0.1) | −0.12 | .09 |
aFor symptoms, quality of life, sport and recreation, self-efficacy, active pain coping, and locus of control, a higher score indicates an improvement. For sedentary behavior, tiredness, pain, passive pain coping, anxiety and depression a lower score indicates an improvement. Results are based on GEE analyses and adjusted for corresponding baseline variables, age, OA location, and gender.
bI-C: difference between intervention and control group.